OXi4503 is currently being investigated in an investigator sponsored Phase 1 study of OXi4503 for the treatment of patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).  The open-label, dose-escalating study, which isbeing conducted by researchers at the University of Florida and is sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program, will be conducted in patients with relapsed or refractory AML or MDS and will evaluate the safety profile, maximum tolerated dose (MTD) and biologic activity of OXi4503. For more information on this ongoing study, please visit our clinical trials page.

OXi4503 (combretastatin A1 di-phosphate / CA1P) is a dual-mechanism vascular disrupting agent that is being developed in clinical trials for the treatment of leukemias. Like its structural analog, ZYBRESTAT, OXi4503 has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis. In addition, in preclinical studies published in the journal Blood, OXi4503 demonstrated potent activity against AML in animal models.

In this preclinical study, researchers administered OXi4503 to mice that were carriers of human AML, which were then studied for disease regression. The data from these models showed that OXi4503 produced remissions in AML models of differing subtypes, including those with activating mutations in the high-risk subtype FLT3.

Additional information regarding the study can be found online at http://news.medinfo.ufl.edu/articles/from-the-lab/uf-oncologists-fight-leukemia-with-two-pronged-therapy-clinical-trials-to-start-within-months/.